Skip to content
value.today

Aytu Bioscience: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $129 M to $581 M, median $287 MPrice to bookPrice to book of Biotechnology: $109 M to $435 M, median $161 M$0 M$157 M$314 M$471 M$627 MMarket value $21 M

Your own DCF model

A full discounted-cash-flow model of Aytu Bioscience, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Aytu Bioscience's own figures of FY2026.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Aytu BioscienceApplied toValue (25th to 75th)Companies
Price to sales2.2× / 5.0× / 10.1×0.4×revenue $58 M$129 M to $581 M85
Price to book3.1× / 4.5× / 12.3×0.6×book equity $35 M$109 M to $435 M70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Aytu Bioscience's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

0.4×

Now above its median of 0.3×; range 0.1× to 3.7× over 30 months.

0×1×2×3×4×2020202120222023202420252026Price to sales 0×Median 0×

Price to book

0.6×

Now below its median of 0.7×; range 0.2× to 3.1× over 30 months.

0×1×2×2×3×2020202120222023202420252026Price to book 1×Median 1×

as of Oct 26, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 26, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2026to Jun 30, 2026$58 M$-14 M$3 M$0 M$3 M$-17 MSEC annual report (10-K, 20-F)
FY2025to Jun 30, 2025$66 M$-14 M$-2 M$0 M$-2 M$-20 MSEC annual report (10-K, 20-F)
FY2024to Jun 30, 2024$65 M$-16 M$-1 M$0 M$-2 M$-9 MSEC annual report (10-K, 20-F)
FY2023to Jun 30, 2023$107 M$-17 M$-5 M——$-8 MSEC annual report (10-K, 20-F)
FY2022to Jun 30, 2022$97 M$-109 M$-29 M$0 M$-29 M$-4 MSEC annual report (10-K, 20-F)
FY2021to Jun 30, 2021$66 M$-58 M$-26 M$2 M$-28 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $21 M on Oct 26, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.